Cantor Fitzgerald Predicts Verona Pharma FY2025 Earnings

Verona Pharma plc (NASDAQ:VRNA) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Verona Pharma in a report issued on Wednesday, June 11th. Cantor Fitzgerald analyst O. Brayer now forecasts that the company will post earnings per share of $0.14 for the year, up from their prior forecast of $0.10. Cantor Fitzgerald has a “Overweight” rating and a $100.00 price target on the stock. The consensus estimate for Verona Pharma’s current full-year earnings is ($1.95) per share. Cantor Fitzgerald also issued estimates for Verona Pharma’s FY2026 earnings at $1.31 EPS.

A number of other research analysts have also recently issued reports on the stock. Wells Fargo & Company lifted their target price on shares of Verona Pharma from $93.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, April 30th. Jefferies Financial Group lifted their target price on shares of Verona Pharma from $95.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday. Cowen started coverage on shares of Verona Pharma in a research note on Monday, April 28th. They issued a “buy” rating for the company. TD Cowen started coverage on shares of Verona Pharma in a research note on Monday, April 28th. They issued a “buy” rating and a $100.00 target price for the company. Finally, Roth Capital set a $83.00 target price on shares of Verona Pharma in a research note on Friday, February 28th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $87.44.

Verona Pharma Stock Down 0.3%

Shares of VRNA opened at $92.20 on Friday. Verona Pharma has a 12 month low of $14.14 and a 12 month high of $93.74. The company has a 50-day moving average price of $71.08 and a two-hundred day moving average price of $60.26. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. The stock has a market cap of $7.48 billion, a price-to-earnings ratio of -48.02 and a beta of 0.21.

Verona Pharma (NASDAQ:VRNA) last released its earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.49. The firm had revenue of $98.65 million for the quarter, compared to analyst estimates of $41.47 million.

Insider Activity

In other news, General Counsel Andrew Fisher sold 26,072 shares of the company’s stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $8.98, for a total value of $234,126.56. Following the sale, the general counsel now directly owns 359,993 shares of the company’s stock, valued at approximately $3,232,737.14. This represents a 6.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David Zaccardelli sold 90,360 shares of the company’s stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $8.98, for a total transaction of $811,432.80. Following the completion of the sale, the chief executive officer now directly owns 14,377,176 shares in the company, valued at approximately $129,107,040.48. The trade was a 0.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,885,800 shares of company stock valued at $19,134,481 in the last quarter. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. NBC Securities Inc. bought a new position in Verona Pharma in the 1st quarter valued at about $34,000. Geneos Wealth Management Inc. raised its holdings in Verona Pharma by 44.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock valued at $40,000 after acquiring an additional 193 shares during the period. Vermillion Wealth Management Inc. bought a new position in Verona Pharma in the 4th quarter valued at about $46,000. Acadian Asset Management LLC bought a new position in Verona Pharma in the 1st quarter valued at about $48,000. Finally, NewEdge Advisors LLC bought a new position in Verona Pharma in the 1st quarter valued at about $58,000. 85.88% of the stock is owned by institutional investors.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.